Patents by Inventor Gautam Mitra
Gautam Mitra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7912272Abstract: A currency genuineness detection system using plurality of opto-electronic sensors with both transmission and reflective (including fluorescence) properties of security documents is developed. Both detection sensing strategies utilize integrated response of the wide optical band sensed under UV visible along with optional near infra red light illumination. A security document is examined under static condition. A window signal signature is thus possible from photodetectors responses for various kinds of documents of different denominations, kinds and country of origin. A programmable technique for checking the genuineness of a security document is possible by feeding a unique code of the currency under examination.Type: GrantFiled: December 28, 2009Date of Patent: March 22, 2011Assignee: Council of Scientific & Industrial ResearchInventors: Murli Manohar Joshi, Ram Prakash Bajpai, Gautam Mitra, Harish Kumar Sardana, Hari Narayan Bhargaw, Saroj Batra
-
Publication number: 20100104170Abstract: A currency genuineness detection system using plurality of opto-electronic sensors with both transmission and reflective (including fluorescence) properties of security documents is developed. Both detection sensing strategies utilize integrated response of the wide optical band sensed under UV visible along with optional near infra red light illumination. A security document is examined under static condition. A window signal signature is thus possible from photodetectors responses for various kinds of documents of different denominations, kinds and country of origin. A programmable technique for checking the genuineness of a security document is possible by feeding a unique code of the currency under examination.Type: ApplicationFiled: December 28, 2009Publication date: April 29, 2010Inventors: Murli Manohar JOSHI, Ram Prakash Bajpal, Gautam Mitra, Harish Kumar Sardana, Hari Narayan Bhargaw, Saroj Batra
-
Patent number: 7650027Abstract: A currency genuineness detection system using plurality of opto-electronic sensors with both transmission and reflective (including fluorescence) properties of security documents is developed. Both detection sensing strategies utilise integrated response of the wide optical band sensed under UV visible along with optional near infra red light illumination. A security document is examined under static condition. A window signal signature is thus possible from photodetectors responses for various kinds of documents of different denominations, kinds and country of origin. A programmable technique for checking the genuineness of a security document is possible by feeding a unique code of the currency under examination.Type: GrantFiled: November 1, 2005Date of Patent: January 19, 2010Assignee: Council of Scientific & Industrial ResearchInventors: Murli Manohar Joshi, Ram Prakash Bajpai, Gautam Mitra, Harish Kumar Sardana, Hari Narayan Bhargaw, Saroj Batra
-
Publication number: 20060159329Abstract: A currency genuineness detection system using plurality of opto-electronic sensors with both transmission and reflective (including fluorescence) properties of security documents is developed. Both detection sensing strategies utilise integrated response of the wide optical band sensed under UV visible along with optional near infra red light illumination. A security document is examined under static condition. A window signal signature is thus possible from photodetectors responses for various kinds of documents of different denominations, kinds and country of origin. A programmable technique for checking the genuineness of a security document is possible by feeding a unique code of the currency under examination.Type: ApplicationFiled: November 1, 2005Publication date: July 20, 2006Inventors: Murli Joshi, Ram Bajpai, Gautam Mitra, Harish Sardana, Hari Bhargaw, Saroj Batra
-
Publication number: 20060115139Abstract: A system for automatic detection of authenticity of security documents by measuring reflected components of incident energy in three or more optical wave bands. The system involves the use of UV-visible light source, an optional near infra red light source, photodetectors and associated sensing circuitry. Photoelectric signals generated by photodetectors from the reflected energy received from a security document are used to verify its authenticity under UV-visible along with optional near infra red illumination. The process involves measurement of energy reflected as photoelectric signals from a security document in at least three optical wavebands by suitably located photodetectors with appropriate wave band filters and the electronic signal processing to distinguish between a genuine document from a fake one for ultimate LED indicator display and audio-visual alarms, hence the detection of fake security document.Type: ApplicationFiled: November 4, 2005Publication date: June 1, 2006Inventors: Murli Joshi, Ram Bajpai, Gautam Mitra, Harish Sardana, Hari Bhargaw, Saroj Batra
-
Patent number: 5419906Abstract: The effects of Cohn-Oncley cold alcohol fractionation on infectivity of two prototype retroviruses, mouse xenotropic type C and the LAV strain of AIDS retrovirus result in a significant reduction in retrovirus titer. At least a 100,000-fold reduction of LAV was obtained when fractionating plasma to fraction II. Adjustment to pH 4.0 at filtrate III was as effective for viral inactivation as was precipitation of fraction II from filtrate III with 25% ethanol. Liquid immunoglobulin preparations spiked with LAV and incubated at 27.degree. C. for 3 days resulted in an additional 1,000-10,000-fold reduction of LAV titer. Our results support the clinical and epidemiological evidence that therapeutic immunoglobulin preparations prepared by Cohn-Oncley cold ethanol processing (at least about 18% v/v alcohol, pH.ltoreq.5.4) and then stored at a pH equal to or less than about 5.4 and a temperature of at least 27.degree. C. for at least 3 days, do not transmit retroviruses such as the LAV strain of the AIDS virus.Type: GrantFiled: October 23, 1992Date of Patent: May 30, 1995Assignee: Miles Inc.Inventors: Gautam Mitra, Milton M. Mozen, Robert E. Louie
-
Patent number: 5159064Abstract: Antibodies, including monoclonal antibodies (Mabs), can be made substantially free of infectious viruses by storing them in a liquid state at conditions of pH, temperature and time sufficient to inactive substantially all infectious viruses. Preferred inactivation methods involve use of a pH equal to or less than about 4.0 at a temperature of at least about 5.degree. C. for at least about 16 hours.Type: GrantFiled: January 29, 1990Date of Patent: October 27, 1992Assignee: Miles Inc.Inventors: Gautam Mitra, Milton M. Mozen
-
Patent number: 5157113Abstract: An essentially pure and stablized antibody preparation comprising IgM antibodies having a purity greater than about 98% by weight and a nucleic acid content of less than about 200 pg per mg IgM. In one embodiment IgM antibodies from a monoclonal source are subjected to ion exchange and size exclusion chromatography at an alkaline pH to yield a purified IgM having a nucleic acid content of less than 10 pg/mg IgM, preferably less than about 4 pg/mg IgM. A highly purified and stabilized preparation of anti Pseudomonas aeruginosa antibodies is disclosed. The removal of nucleic acids is assured by subjecting the antibody source to at least one and preferably two low pH precipitation steps. In a very preferred embodiment, ion exchange and/or size exclusion chromatography is used to remove any residual nucleic acids.Type: GrantFiled: April 12, 1991Date of Patent: October 20, 1992Assignee: Miles Inc.Inventors: George Dove, Gautam Mitra
-
Patent number: 5115101Abstract: Antibody preparation purified using immobilized protein A and yet substantially free of protein A that may have solubilized during the purificaiton process. The antibodies include less than 15 ng protein A per mg of antibody, preferably less than 1 ng/mg. Low protein A content is obtained by first contacting the antibodies and solubilized protein A with an ion exchange resin under conditions to adsorb both. The antibodies and protein A are then sequentially eluted under conditions of increasing ionic strength.Type: GrantFiled: June 26, 1991Date of Patent: May 19, 1992Assignee: Miles Inc.Inventors: James W. Bloom, Melvin F. Wong, Gautam Mitra
-
Patent number: 5006472Abstract: Controlled enzymatic treatment may be used to selectively degrade undesirable contaminants to a size or charge range which can be more readily removed by subsequent separation steps. Treatment is especially useful for purifying rDNA or monoclonal antibody culture products by using nuclease enzyme treatment to degrade undesirable residual nucleic acids to a molecular size or charge range sufficiently different from the product to be purified so that this difference can be exploited in a subsequent purification step (e.g. precipitation, size exclusion chromatography or ion exchange chromatography). The nuclease enzyme treatment is done in the presence of a detergent.Type: GrantFiled: June 3, 1988Date of Patent: April 9, 1991Assignee: Miles Inc.Inventors: George B. Dove, Gautam Mitra
-
Patent number: 4983722Abstract: Protein A is selectively isolated from an antibody--Protein A mixture by exposing the mixture to an anion exchange material under conditions sufficient to adsorb both components and then sequentially eluting the antibodies and protein A under conditions of increasing ionic strength. Resulting antibody preparations have less than about 15 ng of Protein A per mg of antibody.Type: GrantFiled: June 8, 1988Date of Patent: January 8, 1991Assignee: Miles Inc.Inventors: James W. Bloom, Melvin F. Wong, Gautam Mitra
-
Patent number: 4948877Abstract: Immune serum globulins (ISG) can be made substantially free of infectious retroviruses by storing the ISG in a liquid state at conditions of pH, temperature and time sufficient to inactivate substantially all infectious retroviruses. Preferred inactivation methods involve use of either of two specified storage conditions: (1) at a pH equal to or less than about 4.25 at a temperature of about 27.degree. C. for at least 3 days, or (2) at a pH equal to or less than about 6.8 at a temperature of about 45.degree. C. for at least about 8 hours.Type: GrantFiled: May 9, 1988Date of Patent: August 14, 1990Assignee: Miles Laboratories, Inc.Inventors: Gautam Mitra, Milton M. Mozen
-
Patent number: 4762714Abstract: Immune serum globulins (ISG) can be made substantially free of infectious retroviruses by preparing the ISG from human plasma using a cold ethanol plasma fractionation process at a pH equal to or less than 5.4 and then storing the ISG at either of two specified storage conditions: (1) at a pH equal to or less than about 4.25 at a temperature of about 27.degree. C. for at least 3 days, or (2) at a pH equal to or less than about 6.8 at a temperature of about 45.degree. C. for at least about 8 hours.Type: GrantFiled: April 8, 1986Date of Patent: August 9, 1988Assignee: Miles Laboratories, Inc.Inventors: Gautam Mitra, Milton M. Mozen
-
Patent number: 4689323Abstract: There is disclosed a process for producing a convalently bound heparin--antithrombin-III complex useful for anticoagulant therapy, a covalently bound heparin--antithrombin-III complex produced by the process, a composition thereof in a pharmaceutically acceptable carrier, and a method for preventing and treating thromboembolisms by administering to a human patient a therapeutically effective amount of the complex or preparation.Type: GrantFiled: September 26, 1983Date of Patent: August 25, 1987Assignee: Miles Laboratories, Inc.Inventors: Gautam Mitra, Robert E. Jordan
-
Patent number: 4684723Abstract: There is disclosed an improved method for separating and recovering proteins, particularly therapeutically active proteins, from an aqueous system also containing a component having the ability to create two liquid phases by use of salt partitioning technology. By the addition of water soluble inorganic salts to an aqueous system containing one or more therapeutically active proteins or nucleic acids, especially an aqueous system obtained from fractionation of a blood plasma fraction or from a tissue culture fluid resulting from a biotechnology production operation such as recombinant DNA and monoclonal antibody technologies, the aqueous system may be separated into two or more liquid phases. Such separated phases may be selectively enriched in components of the original aqueous system having differing solubility in the so-separated liquid phases.Type: GrantFiled: September 11, 1985Date of Patent: August 4, 1987Assignee: Miles Laboratories, Inc.Inventors: George B. Dove, Gautam Mitra
-
Patent number: 4543210Abstract: There is disclosed an improved process for producing high purity antihemophilic factor concentrate from an antihemophilic factor-containing dispersion or solution isolated from blood plasma or a blood plasma fraction, wherein the improvement is in carrying-out two consecutive precipitations using a combination of precipitants in each precipitation, first a combination of 1-4% by weight, based on weight of solution, of polyethylene glycol and 0.1-0.2 ml of 1-3%, based on weight of suspension, aluminum hydroxide suspension per gram of protein in the starting dispersion or solution, followed by a combination of added polyethylene glycol to provide a final concentration of 9-13% by weight, based on weight of the resulting solution, and 10-20% by weight of glycine, based on weight of the polyethylene glycol solution, and 10-20% by weight, based on weight of the polyethylene glycol solution, of sodium chloride.Type: GrantFiled: October 4, 1984Date of Patent: September 24, 1985Assignee: Miles Laboratories, Inc.Inventors: Gautam Mitra, Paul K. Ng
-
Patent number: 4496689Abstract: There is disclosed a process for producing a covalently attached alpha-1-proteinase inhibitor - water soluble polymer complex useful for pulmonary emphysema therapy, a covalently attached alpha-1-proteinase inhibitor - water soluble polymer complex produced by the process, a composition thereof in a pharmaceutically acceptable carrier, and a method for treating pulmonary emphysema by administering to a human patient a therapeutically effective amount of the complex or preparation.Type: GrantFiled: December 27, 1983Date of Patent: January 29, 1985Assignee: Miles Laboratories, Inc.Inventor: Gautam Mitra
-
Patent number: 4470968Abstract: Compositions containing a concentrate of coagulation Factors II, VII, IX, and X are pasteurized without substantial loss of therapeutic activity by mixing the protein composition with a pasteurization-stabilizing amount of a polyol and a source of citrate ions prior to pasteurization. Pasteurized compositions containing a concentrate of coagulation Factors II, VII, IX, and X, which have heretofore been unattainable, can be prepared by the method of the invention.Type: GrantFiled: January 13, 1983Date of Patent: September 11, 1984Assignee: Miles Laboratories, Inc.Inventors: Gautam Mitra, Paul K. Ng
-
Patent number: 4455301Abstract: Novel antihemophilic factor concentrates and process for making the same are disclosed. An aqueous solution of anithemophilic factor proteins is obtained, preferably by solubilizing antihemophilic factor proteins from blood plasma cryoprecipitate in water. The aqueous solution is purified to remove unwanted protein, for example, by mixing the aqueous solution with aluminum hydroxide. Then, the aqueous solution is ultrafiltered to concentrate it, mixed with buffer and saline and adjusted to an acid pH, and freeze-dried.Type: GrantFiled: September 29, 1982Date of Patent: June 19, 1984Assignee: Cutter Laboratories, Inc.Inventors: Gautam Mitra, John L. Lundblad
-
Patent number: 4404132Abstract: This disclosure pertains to a concentrate for controlling bleeding in hemophilia, free of thrombin, heparin, thromboplastin activity, anticomplement activity, depressor activity, and activated Factor X, and containing coagulation Factors II, VII, IX, and X in non-activated form and containing no greater amounts of calcium-activated factors and Factor VIII Inhibitor Bypassing Activity substance than that found in concentrates of Factor II, VII, IX, and XI that have not been treated, respectively, with calcium or a material which would produce a Factor VIII Inhibitor Bypassing Activity substance in such concentrates and having a specific activity of at least about 1.5 Factor IX units per milligram of total protein and a Factor IX:Factor VII ratio of at least about 6:1, a Factor IX:Factor II ratio of about 1:1 to 2:1, and a Factor IX:NAPTT ratio of at least about 5:1 on a Units per milliliter basis, a Factor II Specific Activity of about 1.0-4.Type: GrantFiled: February 5, 1982Date of Patent: September 13, 1983Assignee: Cutter Laboratories, Inc.Inventor: Gautam Mitra